

Development of divalent LecA ligands as antivirulence agents against *Pseudomonas aeruginosa*

Alexander TITZ [1], Winfried RÖMER [2], Eva ZAHORSKA [1-3], Francesca ROSATO [4,5], Kai STÖBER [4,5], Sakonwan KUHAUDOMLARP [6-8], Saverio MINERVINI [1], Sultaan YOUSAF [1], Martin LEPSIK [6,9], Joscha MEIERS [1-3], Dirk HAUCK [1-2], Emilie GILLON [6], Katharina ROX [2,10], Thorsten KINSINGER [1], Anna K. H. HIRSCH [2,11-12], Anne IMBERTY [6]

[1] *Chemical Biology of Carbohydrates (CBCH)*, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany; [2] *Deutsches Zentrum für Infektionsforschung (DZIF)*, Standort Hannover-Braunschweig; [3] *Department of Chemistry*, Saarland University, D-66123 Saarbrücken, Germany; [4] *Faculty of Biology*, University of Freiburg, 79104 Freiburg, Germany; [5] *Signalling Research Centers BIOS and CIBSS*, University of Freiburg, 79104 Freiburg, Germany; [6] *Université Grenoble Alpes, CNRS, CERMAV*, 38000 Grenoble, France; [7] *Department of Biochemistry, Faculty of Science, Mahidol University*, Bangkok 10400, Thailand; [8] *Center for Excellence in Protein and Enzyme Technology, Faculty of Science, Mahidol University*, Bangkok 10400, Thailand; [9] *Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences*, 160 00 Prague, Czechia; [10] *Department of Chemical Biology (CBIO)*, Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany; [11] *Department of Pharmacy*, Saarland University, D-66123 Saarbrücken, Germany; [12] *Drug Design and Optimization (DDOP)*, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany

alexander.titz@helmholtz-hzi.de

winfried.roemer@bioss.uni-freiburg.de

The Gram-negative bacterium *Pseudomonas aeruginosa* is a critical threat for mankind. Chronic infections are characterized by biofilm formation, a major virulence factor of *P. aeruginosa*, which leads to extensive drug resistance. The tetrameric *P. aeruginosa* lectin LecA is a virulence factor and an anti-biofilm drug target. Increasing the overall binding affinity by multivalent presentation of binding epitopes can enhance the weak carbohydrate–ligand interactions. Low-nanomolar divalent LecA inhibitors with up to 260-fold valency-normalized potency boost and excellent selectivity over human galectin-1 were synthesized from D-galactose pentaacetate and benzaldehyde-based linkers in four linear steps. However, these molecules displayed an intrinsic pH-dependent chemical instability due to their design for dynamic combinatorial assembly, and furthermore, a very low aqueous solubility. Therefore, the acylhydrazone linking motif was isosterically replaced with a more stable amide bond and the linking unit between two galactosides was also varied. The resulting optimized divalent LecA ligands retained low-nanomolar binding affinities, showed improved metabolic stability and were up to 1000-fold more soluble. The lead compound inhibited LecA adhesion to lung cells, restored wound closure in a scratch assay and reduced *P. aeruginosa* invasiveness to host cells *in-vitro*.

Bibliographic references:

Zahorska et al., *Angew. Chem. Int. Ed. Engl.* 2023, doi: 10.1002/anie.202215535.
Zahorska et al., *Chem. Commun.* 2020, 56, 8822.